Serum Total and Free Prostate-specific Antigen for Breast Cancer Diagnosis in Women

• Published in: Clinical cancer research Vol. 6; no. 2; pp. 467 - 473
• Main Authors: BLACK, M. H, GIAI, M, PONZONE, R, SISMONDI, P, HE YU, DIAMANDIS, E. P
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.02.2000
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Breast Neoplasms - blood; Breast Neoplasms - diagnosis; Breast Neoplasms - surgery; Diagnosis, Differential; Female; Fibrocystic Breast Disease - blood; Follow-Up Studies; Gynecology. Andrology. Obstetrics; Humans; Leiomyoma - blood; Mammary gland diseases; Medical sciences; Middle Aged; Prostate-Specific Antigen - blood; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Tumors; Uterine Neoplasms - blood; Human; Serine endopeptidases; Enzyme; Free form; α1-Antichymotrypsin; Enzyme inhibitor; Malignant tumor; Blood; Bound form; Prostate specific antigen; Mammary gland diseases; Peptidases; Total; Hydrolases; Female; Serum; Diagnosis; Mammary gland
• ISSN: 1078-0432; 1557-3265

Prostate-specific antigen (PSA) is a serine protease expressed at high levels in prostate epithelium, and elevated PSA in serum is a well-established marker of prostate cancer. Recently, the relative proportions of free PSA and PSA complexed to the serine protease inhibitorα 1 -antichymotrypsin have become important variables in distinguishing between prostate cancer and benign prostatic hyperplasia. Numerous studies have demonstrated the production of PSA in female tissues such as the breast, and low levels of PSA are present in female sera. The objective of this study was to measure and compare the relative proportions of free PSA and PSA complexed to the serine protease inhibitor α 1 -antichymotrypsin in the serum of women with breast cancer or benign breast disease or women with no known malignancies. PSA was measured with an established immunoassay for total PSA and a novel immunoassay for free PSA, both of which had a detection limit of 0.001 μg/liter (1 ng/liter). The percentage of breast cancer patients with free PSA as the predominant molecular form (>50% of total PSA) in serum was five times higher than that of healthy women or women with benign breast disease, and PSA decreased in the serum of breast cancer patients after surgery. The diagnostic use of free PSA for breast cancer is limited at this point, due to the low diagnostic sensitivity (∼20%); however, free PSA as the predominant molecular form shows a high diagnostic specificity (∼96%) in comparison to women free of breast cancer or with benign breast disease. These results suggest that the clinical applicability of free PSA for breast cancer diagnosis and the biological mechanism behind its increase should be further investigated.